Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - June 12, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the " MCTO ") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order (" NP 12-203 "). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the " Annual Filings ") beyond the period prescribed under applicable Canadian securities laws (the " Default Announcement "). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about June 26, 2025. The Company is also progressing on completion of its interim financial statements and accompanying management's discussion and analysis for the first quarter ended March 31, 2025, and will provide a further update on or about June 26, 2025. Further updates on timing will be provided by the Company as necessary.» Mehr auf thenewswire.com
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - May 29, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the " MCTO ") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order (" NP 12-203 "). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the " Annual Filings ") beyond the period prescribed under applicable Canadian securities laws (the " Default Announcement "). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about June 12, 2025. The Company is also progressing on completion of its interim financial statements and accompanying management's discussion and analysis for the first quarter ended March 31, 2025, and will provide a further update on or about June 12, 2025. Further updates on timing will be provided by the Company as necessary.» Mehr auf thenewswire.com
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - May 15, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the " MCTO ") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order (" NP 12-203 "). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the " Annual Filings ") beyond the period prescribed under applicable Canadian securities laws (the " Default Announcement "). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about May 29, 2025. The Company is also progressing on completion of its interim financial statements and accompanying management's discussion and analysis for the first quarter ended March 31, 2025, and will provide a further update on or about May 29, 2025. Further updates on timing will be provided by the Company as necessary.» Mehr auf thenewswire.com

Historische Dividenden

Alle Dividenden Kennzahlen

In 2022 hat Mydecine Innovations Group Aktie 0,23€ Dividende ausgeschüttet. Die letzte Dividende wurde im März 2022 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Mydecine Innovations Group Aktie einen Umsatz von 0,00€ und ein Nettoeinkommen von −1,32 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	-
Nettoeinkommen	−1,32 Mio	-
EBITDA	−1,06 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+114,13k€
Anzahl Aktien	26,46 Mio
52 Wochen-Hoch/Tief	+0,0138€ - +0,000863€
Dividenden	Nein
Beta	2,33
KGV (PE Ratio)	−0,68
KGWV (PEG Ratio)	−0,04
KBV (PB Ratio)	−0,55
KUV (PS Ratio)	0,00

Unternehmensprofil

Mydecine Innovations Group Inc. ist ein Biotechnologie- und Biowissenschaftsunternehmen, das sich mit der Entwicklung und Vermarktung von Medikamenten zur Behandlung psychischer Probleme befasst. Das Unternehmen entwickelt Therapien für Veteranen, medizinische Notfalldienste, posttraumatische Belastungsstörungen und Arbeiter an vorderster Front und betreibt Mindleap, eine digitale Telegesundheitsplattform, die Zugang zu psychischen Gesundheitsdiensten sowie psychedelischen Integrationsdiensten, einschließlich psychedelischer Nachsorge- und Wellnessdienste, bietet. Das Unternehmen beschäftigt sich auch mit der Entdeckung von Medikamenten und entwickelt psychedelisch unterstützte Therapeutika, Wirkstoffe, Therapieprotokolle und einzigartige Verabreichungssysteme auf natürlicher Basis. Darüber hinaus betreibt es eine Hanffarm in Pottus, Texas. Mydecine Innovations Group Inc. hat eine Partnerschaft mit dem Leiden University Medical Center, dem Royal Ottawa Mental Health Centre, LeadGen Labs zur Unterstützung der Entwicklung psychedelischer Arzneimittel und Applied Pharmaceutical Innovation für die Entwicklung von Arzneimitteln und klinischen Studienprogrammen. Das Unternehmen war früher als NewLeaf Brands Inc. bekannt und änderte im Juni 2020 seinen Namen in Mydecine Innovations Group Inc. Mydecine Innovations Group Inc. wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.